Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hepatobiliary Pancreat Dis Int. 2009 Dec;8(6):591-6.
Although hepatic resection is widely accepted as a proper modality for treating hepatocellular carcinoma (HCC), a majority of patients are unable to undergo surgical resection due to various tumor and patient factors. Radiofrequency ablation (RFA) has mostly been used as a therapeutic alternative to resection for treating HCC. The objective of this study was to evaluate the results of intraoperative RFA for HCCs in locations difficult for a percutaneous approach.
Eight patients (male, seven; age, 49-67 years) with 8 HCCs in difficult locations were treated by intraoperative RFA. Six of the patients had local tumor progression after initial transarterial chemoembolization or ultrasound (US) guided percutaneous RFA. The locations of the tumors were hepatic dome in six patients, posterior subcapsule in one, and caudate lobe in one. The tumor size was 2.0 to 6.4 cm (mean, 3.9 cm). Intraoperative RFA was performed at the tumor itself and an anticipated resection line under US guidance with 3 cm monopolar single or clustered internally cooled electrodes. Tumor resection was performed in six patients. One month later, treatment response was assessed by contrast material-enhanced computed tomography (CT). CT studies were performed every 2 or 3 months after RFA.
RFA was technically successful in all tumors, and the contrast-enhanced CT images acquired one month later showed complete disappearance of tumor enhancement. One pneumothorax occurred. After a median follow-up of 18 months (range, 6-30 months), no tumors showed local progression. During the follow-up period, four new recurrent tumors were observed in three patients. Four patients were alive at the time of this report and the other four died of hepatorenal syndrome, liver failure, and progression of new recurrent tumors.
Intraoperative RFA with tumor resection can be an alterative treatment option for HCC in locations difficult for a percutaneous approach.
尽管肝切除术被广泛认为是治疗肝细胞癌(HCC)的合适方法,但由于各种肿瘤和患者因素,大多数患者无法进行手术切除。射频消融(RFA)主要被用作切除治疗 HCC 的替代疗法。本研究的目的是评估经皮途径困难部位 HCC 行术中 RFA 的结果。
8 例(男 7 例;年龄 49-67 岁)8 个 HCC 位于困难部位,采用术中 RFA 治疗。6 例患者在初始经动脉化疗栓塞或超声(US)引导经皮 RFA 后出现局部肿瘤进展。肿瘤位置 6 例位于肝顶,1 例位于后包膜下,1 例位于尾状叶。肿瘤大小 2.0-6.4cm(平均 3.9cm)。在 US 引导下,使用 3cm 单极单或簇状内部冷却电极在肿瘤本身和预期的切除线处进行术中 RFA。6 例患者行肿瘤切除术。术后 1 个月,采用增强 CT 评估治疗反应。RFA 后每 2-3 个月进行 CT 检查。
所有肿瘤的 RFA 均技术成功,术后 1 个月增强 CT 图像显示肿瘤完全消失。1 例发生气胸。中位随访 18 个月(范围 6-30 个月)后,无肿瘤局部进展。随访期间,3 例患者中发现 4 个新复发肿瘤。截至报告时,4 例患者存活,另外 4 例患者因肝肾综合征、肝功能衰竭和新复发肿瘤进展而死亡。
对于经皮途径困难部位的 HCC,术中 RFA 联合肿瘤切除术是一种替代治疗选择。